Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irinotecan + epirubicin
- Development stage
- Phase 2
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination regimen of two chemotherapeutic agents, irinotecan and epirubicin. Irinotecan is a topoisomerase I inhibitor that prevents DNA from unwinding, thereby inhibiting DNA replication and transcription in cancer cells. Epirubicin is an anthracycline antibiotic that intercalates into DNA, inhibits topoisomerase II, and generates free radicals leading to cytotoxicity. The combination may be used in investigational or off-label settings for the treatment of various cancers, particularly solid tumors such as gastrointestinal malignancies.
- Other names
- IRI + EPI
02
Targets
DNATOP1 (DNA Topoisomerase I)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on irinotecan + epirubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irinotecan + epirubicin.